Conferences

IAS 2021

The 11th International AIDS Society Conference on HIV Science (IAS 2021) was held virtually from 18-21 July 2021. NAM aidsmap was an official scientific media partner for IAS 2021.
IAS 2021
New & experimental HIV treatments

Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing therapy

Antibody-based prevention

HIV vaccines and immunotherapies “would be further along” if they had the resources of COVID-19, says leading antibody researcher

The search for a cure

Could gene therapies be used to cure more people with HIV?

PrEP science

Conclusive PrEP study in China paves the way for national provision for gay men

Economic & social inequality

Cash transfers result in reduced AIDS cases, hospitalisations and deaths among Brazil’s poorest

Vaginal rings & topical PrEP

Young women and pregnant women can effectively use vaginal rings and oral PrEP for HIV prevention

Health problems in children & young people

More insulin resistance and worse metabolic profiles in children with HIV, South African study shows

Chemsex & recreational drug use

Chemsex on the rise in Thailand and other Asian countries

Coronavirus

People with HIV can produce an adequate immune response to SARS-CoV-2

Opportunistic infections

Improved treatment for cryptococcal meningitis, a leading cause of death in people with HIV

The search for a cure

Novel dual antibody therapy partially controls virulent HIV infection in monkeys off treatment

Transgender people

Studies confirm that hormone levels in trans women are not greatly affected by PrEP, or vice versa

Injectable & long-acting PrEP

Modelling suggests injectable cabotegravir is far more effective than daily oral PrEP for women

Transgender people

How can HIV research better align with the realities of transgender and gender-diverse people?

Drug-resistant TB

Shorter, less toxic treatment for highly drug-resistant TB cures nine out of ten

The search for a cure

Earlier treatment and higher CD4 counts linked to smaller HIV reservoir

PrEP science

PrEP failures in African programmes are rare, but some are happening in people with good adherence

Viral load

Viral suppression in Uganda improved by more viral load tests, done faster

Retention & linkage to care

Multiple African countries improved access to HIV treatment during COVID-19 pandemic

Improving HIV care

Long-acting injectable HIV treatment is feasible, even during COVID-19

Coronavirus

Lower CD4 count and unsuppressed HIV raise the risk for severe COVID-19

Improving HIV care

Homeless people with HIV prefer flexibility, in-person care and incentives

PrEP programmes & uptake

Few HIV infections among PrEP users in Brazil and Mexico, but challenges in Peru

Cardiovascular disease

Large UK study identifies increased cardiovascular risk in people living with HIV, including younger people

Injectable & long-acting HIV treatment

Twice-a-year injected drug shows promise for first-line HIV treatment

HIV treatment for children & young people

Adolescent-centred interventions lead to a 30-percentage-point increase in viral suppression in Namibia, and a 20-percentage-point increase in Nigeria

Retention & linkage to care

Healthcare workers in Cape Town ambivalent about patients who disengage from HIV treatment

Coronavirus

People with HIV should be prioritised for COVID-19 vaccination due to higher risk, WHO recommends

Violence

Sexual violence against women and girls in Uganda increased during the COVID-19 pandemic

Elimination of hepatitis C

Hepatitis C virtually eliminated in people with HIV in the Netherlands

Treatment guidelines

Most countries with the greatest burden of HIV still don’t recommend dolutegravir for all

Interviews

IAS 2021: Injectable treatment for multidrug-resistant HIV

23 July 2021

Professor Jean-Michel Molina of Hôpital Saint-Louis in Paris talks about injectable lenacapavir, a capsid inhibitor currently under development, for people with multidrug-resistant HIV at IAS 2021.

IAS 2021: Injectable lenacapavir for people starting HIV treatment

23 July 2021

At IAS 2021, Professor Samir Gupta of Indiana University talks about lenacapavir, an experimental capsid inhibitor, for people starting HIV treatment.

IAS 2021: COVID-19 in people with HIV

23 July 2021

Dr Silvia Bertagnolio of the World Health Organization talks about COVID-19 in people living with HIV at IAS 2021.

IAS 2021: Providing injectable HIV treatment

27 July 2021

At IAS 2021, Dr Maggie Czarnogorski of ViiV Healthcare talks about providing injectable HIV treatment.

IAS 2021: Vaginal rings and oral PrEP

27 July 2021

Dr Lulu Nair of Stellenbosch University in Cape Town talks about vaginal rings and oral pre-exposure prophylaxis (PrEP) at IAS 2021.

Conference bulletins

English

IAS 2021: Twice-yearly treatment injections for multidrug-resistant HIV, Monday 19 July 2021

(HTML)

IAS 2021: Adolescent-centred interventions lead to increase in viral suppression, Tuesday 20 July 2021

(HTML)

IAS 2021: Lower CD4 count and unsuppressed HIV raise risk for severe COVID-19, Wednesday 21 July 2021

(HTML)

IAS 2021: Earlier treatment and higher CD4 counts linked to smaller HIV reservoir, Thursday 22 July 2021

(HTML)

IAS 2021: Improved treatment for cryptococcal meningitis, Wednesday 28 July 2021

(HTML)

French

IAS 2021: Des injections deux fois par an pour le traitement du VIH multirésistant, Lundi 19 juillet 2021

(HTML)

IAS 2021: Les interventions axées sur les adolescents conduisent à une hausse de la suppression virale, Mardi 20 juillet 2021

(HTML)

IAS 2021: Un taux faible de cellules T CD4 et une charge virale détectable augmentent les risques de COVID-19 grave, Mercredi 21 juillet 2021

(HTML)

IAS 2021: Un traitement précoce et un taux de cellules T CD4 élevé sont associés à un réservoir viral plus faible, Jeudi 22 juillet 2021

(HTML)

IAS 2021: Amélioration du traitement de la méningite à cryptocoques, Mercredi 28 juillet 2021

(HTML)

Spanish

IAS 2021: Inyecciones semestrales para tratar el VIH multirresistente a fármacos, Lunes, 19 de julio de 2021

(HTML)

IAS 2021: Las intervenciones centradas en los adolescentes consiguen mejorar las tasas de supresión de la carga viral, Martes, 20 de julio de 2021

(HTML)

IAS 2021: Tener niveles bajos de CD4 y una carga viral del VIH detectable aumentan el riesgo de sufrir un caso grave de COVID-19, Miércoles, 21 de julio de 2021

(HTML)

IAS 2021: Un inicio más temprano del tratamiento y un nivel más elevado de CD4, vinculados a un menor reservorio viral, Jueves, 22 de julio de 2021

(HTML)

IAS 2021: Mejora en el tratamiento de la meningitis criptocócica, Miércoles, 28 de julio de 2021

(HTML)

Italian

IAS 2021: Farmaco iniettabile per il trattamento dell’HIV multifarmacoresistente efficace con due sole somministrazioni all’anno, Lunedì 19 luglio 2021

(HTML)

IAS 2021: Gli interventi mirati sugli adolescenti migliorano la soppressione virale, Martedì 20 luglio 2021

(HTML)

IAS 2021: Rischio di COVID-19 grave più elevato con basse conte CD4 e mancata soppressione HIV, Mercoledì 21 luglio 2021

(HTML)

IAS 2021: Trattamento precoce e conte CD4 più elevate associati a una riduzione dei reservoir HIV, Giovedì 22 luglio 2021

(HTML)

IAS 2021: Un trattamento più efficace per la meningite criptococcica, Mercoledì 28 luglio 2021

(HTML)

Russian

IAS 2021: Инъекционный препарат, применяемый два раза в год, при полирезистентности ВИЧ, Понедельник, 19 июля 2021 г.

(HTML)

IAS 2021: Мероприятия, проводимые среди подростков, приводят к улучшению вирусологического контроля, Вторник, 20 июля 2021 г.

(HTML)

IAS 2021: Низкий уровень CD4 и определяемая вирусная нагрузка повышают риск тяжелого течения COVID-19, Среда, 21 июля 2021 г.

(HTML)

IAS 2021: Раннее начало терапии при более высоких показателях CD4 ассоциируется с меньшим объемом ВИЧ-резервуаров, Четверг, 22 июля 2021 г.

(HTML)

IAS 2021: Лучший вариант лечения криптококкового менингита, Среда 28 июля 2021 г.

(HTML)

Portuguese

IAS 2021: Injeções semestrais de tratamento para o VIH multirresistente, Segunda-feira, 19 de julho de 2021

(HTML)

IAS 2021: Intervenções centradas no adolescente levam ao aumento da supressão viral, Terça-feira, 20 de julho de 2021

(HTML)

IAS 2021: Contagem de CD4 mais baixa e VIH não suprimido aumentam o risco de COVID-19 grave, Quarta-feira, 21 de julho de 2021

(HTML)

IAS 2021: Tratamento precoce e contagens de CD4 mais altas ligadas a um reservatório menor de VIH, Quinta-feira, 22 de julho de 2021

(HTML)

IAS 2021: Tratamento melhorado para meningite criptocócica, Quarta-feira, 28 de julho de 2021

(HTML)